The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.1M data for 1.3M Compounds and 9.6K Targets. Of those, 1.5M data for 698K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Advanced Search

13 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
A review on ROCK-II inhibitors: From molecular modelling to synthesis.EBI
Nirma University
Design, synthesis and pharmacological evaluation of novel substituted quinoline-2-carboxamide derivatives as human dihydroorotate dehydrogenase (hDHODH) inhibitors and anticancer agents.EBI
Nirma University
Telomerase: A prominent oncological target for development of chemotherapeutic agents.EBI
Nirma University
Recent advances in the discovery of small molecule c-Met Kinase inhibitors.EBI
Nirma University
Medicinal chemistry strategies for the development of phosphodiesterase 10A (PDE10A) inhibitors - An update of recent progress.EBI
Nirma University
Systemic review on B-RafEBI
Nirma University
Histone deacetylase 2: A potential therapeutic target for cancer and neurodegenerative disorders.EBI
Nirma University
Medicinal chemistry approaches of poly ADP-Ribose polymerase 1 (PARP1) inhibitors as anticancer agents - A recent update.EBI
Nirma University
Synthesis of 2-,4,-6-, and/or 7-substituted quinoline derivatives as human dihydroorotate dehydrogenase (hDHODH) inhibitors and anticancer agents: 3D QSAR-assisted design.EBI
Nirma University
A comprehensive review on Aurora kinase: Small molecule inhibitors and clinical trial studies.EBI
Nirma University
Recent updates for designing CCR5 antagonists as anti-retroviral agents.EBI
Nirma University
Discovery of a novel class of selective human CB1 inverse agonists.BDB
Vernalis (R&D)